Kyoto University · 의학
H. Matsuo 교수의 연구실은 주로 내분비학 및 종양학 분야에서 활동하며, 뇌하우스 호르몬의 구조와 기능, 특히 LH 및 FSH 분비 조절에 관여하는 페프티드 호르몬의 분자 기전을 연구하고 있습니다. 또한 백혈병, 특히 MLL 유전자 재배열과 관련된 EVI1 및 CEBPA 유전자 변이가 백혈병 발병과 예후에 미치는 영향을 분석하여, 소아 급성 백혈병의 분자 기반 치료 전략 개발에 기여하고 있습니다. 최근에는 류마티스 관절염 환자의 재발을 예측하기 위한 머신러닝 기반 생물정보학적 접근도 시도하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
No AccessJournal of Urology1 Feb 2002Structure of the porcine LH-and FSH-releasing Hormone.I. The proposed amino acid sequence0110 0 H. Matsuo, Y. Baba, R.M.G. Nair, A. Arimura, and A.V. Schally H. MatsuoH. Matsuo V.A. Hospital, New Orleans, LA, USA Tulane University School of Medicine, New Orleans, LA, USA More articles by this author , Y. BabaY. Baba V.A. Hospital, New Orleans, LA, USA Tulane University School of Medicine, New Orleans, LA, USA More articles by this author , R.M.G. NairR.M.G. N
The ecotropic viral integration site-1 gene (EVI1) encodes a zinc finger protein that functions as a transcriptional regulator of hematopoietic stem cell self-renewal and long-term multilineage repopulating activity. The mixed lineage leukemia gene (MLL) rearrangements [i.e. t(11q23)] occur at high frequency in pediatric acute myeloid leukemia (AML) patients with EVI1 overexpression, 3 and EVI1 is a transcriptional target of MLL oncoproteins. 4 EVI1 overexpression has been reported in up to 10%
Recent effective therapies enable most rheumatoid arthritis (RA) patients to achieve remission; however, some patients experience relapse. We aimed to predict relapse in RA patients through machine learning (ML) using data on ultrasound (US) examination and blood test. Overall, 210 patients with RA in remission at baseline were dichotomized into remission (n = 150) and relapse (n = 60) based on the disease activity at 2-year follow-up. Three ML classifiers [Logistic Regression, Random Forest, an
CCAAT/enhancer-binding protein alpha (CEBPA) mutations are a favorable prognostic factor in adult acute myeloid leukemia (AML) patients; however, few studies have examined their significance in pediatric AML patients. Here we examined the CEBPA mutation status and clinical outcomes of pediatric AML patients treated in the AML-05 study. We found that 47 (14.9%) of the 315 evaluable patients harbored mutations in CEBPA; 26 cases (8.3%) harbored a single mutation (CEBPA-single) and 21 (6.7%) harbor
